Immunomodulatory effects of rexinoids

Seminars in Oncology

Volumn 33, Issue SUPPL. 3, 2006, Pages 21-25

  Foss, Francine ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; BEXAROTENE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DIPHENHYDRAMINE; INTERLEUKIN 2 RECEPTOR; PARACETAMOL; PSORALEN; RETINOIC ACID; RETINOID; REXINOID; UNCLASSIFIED DRUG;

CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG RECEPTOR BINDING; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; IMMUNE RESPONSE; LYMPHOMA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PUVA; REVIEW; TREATMENT RESPONSE; VASCULAR DISEASE;

EID: 33644514286     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.12.019     Document Type: Article

References (16)

1. L.T. Farol, K.B. Hymes Bexarotene A clinical review Expert Rev Anticancer Ther 4 2004 180 188
2. P. Chambon The retinoid signaling pathway Molecular and genetic analyses Semin Cell Biol 5 1994 115 125
3. C. Zhang, P. Hazarika, X. Ni Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells Relevance to mechanism of therapeutic action Clin Cancer Res 8 2002 1234 1240
4. N. Sidell, B. Chang, L. Bhatti Upregulation by retinoic acid of interleukin-2 receptor mRNA in human T lymphocytes Cell Immunol 146 1993 28 37
5. G. Gorgun, F. Foss Immunomodulatory effects of RXR rexinoids Modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox Blood 100 2002 1399 1403
6. E. Olsen, M. Duvic, A. Frankel Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 2001 376 388
7. M.N. Saleh, C.F. LeMaistre, T.M. Kuzel Antitumor activity of BAD389IL-2 fusion toxin in mycosis fungoides J Am Acad Dermatol 39 1998 63 73
8. C.F. LeMaistre, M.N. Saleh, T.M. Kuzel Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2 Blood 91 1998 399 405
9. M. Duvic, K. Hymes, P. Heald Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma Multinational phase II-III trial results J Clin Oncol 19 2001 2456 2471
10. M. Duvic, A.G. Martin, Y. Kim Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch Dermatol 137 2001 581 593
11. F. Foss, M.F. Demierre, G. Divenuti A phase I trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma Blood 106 2005 454 457
12. R. Edelson, C. Berger, F. Gasparro Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy Preliminary results N Engl J Med 316 1987 297 303
13. J.A. Zic, G.P. Stricklin, J.P. Greer Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy J Am Acad Dermatol 35 1996 935 945
14. H. DeGrendele Current data with bexarotene (Targretin) in non-small cell lung cancer Clin Lung Cancer 4 2003 210 212
15. J.R. Rigas, K.H. Dragnev Emerging role of rexinoids in non-small cell lung cancer Focus on bexarotene The Oncologist 10 2005 22 33
16. T.-C. Yen, M.R. Corpuz, R.Y. Prudente A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxol (Taxol) resistance in human non-small cell lung cancer Clin Cancer Res 10 2004 8656 8664